invIOs is a private biotech company that specializes in the discovery and development of next-generation cancer therapies.
invIOs has raised $8.9M in total funding. The most recent round was Series A. The last funding was announced in October 2024.
invIOs's investors include Ligand Pharmaceuticals, The Austrian Research Promotion Agency (FFG).
invIOs is headquartered in Vienna, Austria.
invIOs is a private biotech company that specializes in the discovery and development of next-generation cancer therapies.
invIOs is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"invIOs — Funding & Investors." VCBacked, October 15, 2024, https://www.vcbacked.co/company/invios. Accessed August 15, 2026.
VCBacked. (2024). invIOs — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/invios
{{cite web |title=invIOs — Funding & Investors |url=https://www.vcbacked.co/company/invios |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated